J&J selects lead vaccine candidate for COVID-19

30 March 2020
jnjn_flickr_big

Shares of Johnson & Johnson (NYSE: JNJ) were up more than 3.8% at $128.16 in early trading today, after the US healthcare giant announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020.

This marks a significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of J&J and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the company's manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine.

Testing to start in September at latest; $1 billion investment

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical